The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

The following is a summary of “Survival in uveal melanoma patients is linked to genetic variation at HERC2 SNP rs12913832,” published in the September 2024 issue of Ophthalmology by Gelmi et al. Uveal ...

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on IDEAYA Biosciences (IDYA – Research Report). The associated ...

Video content above is prompted by the following: Provide a brief overview of uveal melanoma. What are the risk factors and symptoms? Are there ways to help prevent uveal melanoma? How does it differ ...

With the data and support from the FDA, IDEAYA Biosciences has laid out how its Phase III trial of darovasertib will look.

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) Monday announced positive interim data from a Phase 2 study evaluating darovasertib as neoadjuvant treatment for uveal melanoma (UM). Neoadjuvant therapy is ...

Patients with uveal melanoma face many threats: early death, pain, visual handicap, and facial disfigurement, which result in loss of income and independence, with restrictions on occupational ...

Ideaya Biosciences has reported positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma, or UM, as well as a successful Type C meeting with the Food and Drug ...

AVITA's large addressable market, high gross margins, and low valuation suggest the potential for 154% stock upside. Find out ...

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...